Baxfendy (baxdrostat) Approved in the US as First Aldosterone Synthase Inhibitor for Uncontrolled Hypertension | iPharmaCenter

Baxfendy FDA Approval for Hypertension

 AstraZeneca has received US FDA approval for Baxfendy (baxdrostat), the first and only aldosterone synthase inhibitor (ASI) indicated for the treatment of hypertension in adults whose blood pressure remains uncontrolled despite standard therapies.

Baxfendy is approved for use in combination with other antihypertensive medications, offering a new treatment option for patients with resistant or difficult-to-control hypertension.

Also read: Top 10 Pharmaceutical Companies by Revenue 2025

Unmet Need in Uncontrolled Hypertension

Hypertension affects approximately 1.4 billion people worldwide and remains the leading modifiable risk factor for cardiovascular disease. In the United States, nearly 50% of patients receiving multiple antihypertensive drugs still fail to achieve adequate blood pressure control.

Uncontrolled hypertension significantly increases the risk of heart attack, stroke, heart failure, kidney disease, and premature death, highlighting the urgent need for new treatment approaches.

Baxfendy have Novel Mechanism: Aldosterone Synthase Inhibition

Baxfendy (baxdrostat) is a first-in-class, highly selective aldosterone synthase inhibitor designed to reduce blood pressure by targeting aldosterone production.

Aldosterone is a hormone that regulates salt and fluid balance but, when elevated, contributes to increased blood pressure and cardiovascular risk. By inhibiting aldosterone synthesis, Baxfendy provides a targeted and differentiated mechanism compared to existing therapies.

Also read: BeOne Medicines’ Beqalzi (sonrotoclax) Gets FDA Approval as First BCL2 Inhibitor for Relapsed or Refractory Mantle Cell Lymphoma

BaxHTN Phase III Trial Results

The FDA approval was supported by results from the Phase III BaxHTN trial, which evaluated Baxfendy in patients with uncontrolled or resistant hypertension already receiving at least two antihypertensive medications.

At 12 weeks, Baxfendy demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure:

• 2 mg dose: 15.7 mmHg reduction from baseline; 9.8 mmHg placebo-adjusted reduction

• 1 mg dose: 14.5 mmHg reduction from baseline; 8.7 mmHg placebo-adjusted reduction

• Placebo: 5.8 mmHg reduction

The treatment effect was consistent across both uncontrolled and treatment-resistant patient subgroups.

Baxfendy was generally well tolerated in the clinical trial, with no unexpected safety findings reported, supporting its use alongside standard antihypertensive therapies.

Analysts estimate that Baxfendy (baxdrostat) has the potential to become a blockbuster therapy, with some projecting annual sales approaching $5 billion at peak.

Clinical Significance of Blood Pressure Reduction

Even modest reductions in systolic blood pressure are associated with meaningful decreases in cardiovascular risk. Evidence shows that lowering systolic blood pressure can reduce the incidence of major cardiovascular events, reinforcing the clinical value of effective therapies like Baxfendy.